A head-to-head comparison has found that MRI is more sensitive than FDG-PET/CT for assessment of N-stage non-small cell lung cancer.
A head-to-head comparison has found that MRI is more sensitive than FDG-PET/CT for assessment of N-stage non-small cell lung cancer.
The study at the Kobe University Graduate School of Medicine in Japan involved 115 consecutive lung cancer patients examined with both modalities, said chief investigator Dr. Yoshiharu Ohno. MRI was performed on a 1.5T scanner with black-blood STIR turbo spin-echo and SENSE (sensitivity encoding).
FDG-PET and contrast-enhanced CT studies were acquired using 16-slice CT scanners with images fused by commercial software. Qualitative analysis involved visual interpretation and rating based on a five-point system. Quantitative analysis for both modalities involved signal intensity comparison of lymph nodes and a 0.9% saline phantom placed on patients' chests. Standard uptake values for FDG were performed.
On a per-patient basis, the visual reading of the STIR MRI for mediastinal and hilar lymph node metastasis was significantly better than qualitative interpretation of PET/CT images, Ohno said. The sensitivity of MRI and PET/CT were 83.7% and 69.8%, respectively. Specificities for the two modalities were 87.5% for MRI and 90.3% for PET/CT, but these differences were not large enough to achieve statistical significance.
STIR MRI again proved superior during the quantitative comparison, where its 90.1% sensitivity rate compared with a sensitivity of 72% for PET/CT. Specificities for both modalities were 90.3%.
An ROC analysis revealed the sensitivity, specificity, and accuracy of MRI were significantly high than PET/CT, according to Ohno.
"STIR turbo spin-echo imaging should be considered at least as valuable as PET/CT for assessing N-stage patients with non-small cell lung cancer," he said.
For more information from the Diagnostic Imaging archives:
Multicenter lung cancer trial updates data supporting RFA
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.